Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ (EBioMedicine (2019) 47 (446–456), (S2352396419305912), (10.1016/j.ebiom.2019.08.069))

La Tonya J. Hickson, Larissa G.P. Langhi Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze, Shahrukh K. Hashmi, Sandra M. Herrmann, Michael D. Jensen, Qingyi Jia, Kyra L. Jordan, Todd A. Kellogg, Sundeep Khosla, Daniel M. Koerber, Anthony B. Lagnado, Donna K. Lawson, Nathan K. LeBrasseur, Lilach O. Lerman, Kathleen M. McDonald, Travis J. McKenzie, João F. PassosRobert J. Pignolo, Tamar Pirtskhalava, Ishran M. Saadiq, Kalli K. Schaefer, Stephen C. Textor, Stella G. Victorelli, Tammie L. Volkman, Ailing Xue, Mark A. Wentworth, Erin O. Wissler Gerdes, David B. Allison, Stephanie L. Dickinson, Keisuke Ejima, Elizabeth J. Atkinson, Marc Lenburg, Yi Zhu, Tamara Tchkonia, James L. Kirkland

Research output: Contribution to journalComment/debatepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ (EBioMedicine (2019) 47 (446–456), (S2352396419305912), (10.1016/j.ebiom.2019.08.069))'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds